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Objective: To assess the effectiveness of three mood disorder treatment algorithms in a sample of
patients seeking care in the Brazilian public healthcare system.
Methods: A randomized pragmatic trial was conducted with an algorithm developed for treating
episodes of major depressive disorder (MDD), bipolar depressive episodes and mixed episodes of
bipolar disorder (BD).
Results: The sample consisted of 259 subjects diagnosed with BD or MDD (DSM-IV-TR). After
the onset of symptoms, the first treatment occurred B6 years and the use of mood stabilizers began
B12 years. All proposed algorithms were effective, with response rates around 80%. The majority of
the subjects took 20 weeks to obtain a therapeutic response.
Conclusions: The algorithms were effective with the medications available through the Brazilian
Unified Health System. Because therapeutic response was achieved in most subjects by 20 weeks, a
follow-up period longer than 12 weeks may be required to confirm adequate response to treatment.
Remission of symptoms is still the main desired outcome. Subjects who achieved remission recovered
more rapidly and remained more stable over time.
Clinical trial registration: NCT02901249, NCT02870283, NCT02918097
Keywords: Mood disorders; bipolar; mood disorders; unipolar; clinical drug studies; economic issues;
epidemiology
Introduction
Mood disorders are highly prevalent and are related to
psychological, social and functional impairment. A num-
ber of studies have associated mood disorders with high
economic costs and public healthcare system overload.1,2
Major depressive disorder (MDD) is one of the main causes
of morbidity in the world,3 with lifetime prevalence rates
varying from 3% in Japan to 17% in the United States to
18.3% in Brazil.4 According to the Global Burden of Disease
Study, unipolar depression is currently considered the third
leading cause of medical conditions and is predicted to
be the leading cause in 2030.3 Bipolar disorder (BD) is the
eighth leading cause of disability worldwide, with preva-
lences of about 3% globally5 and 0.9% in Brazil.6
Brazil is the largest country in South America, with a popu-
lation of approximately 190 million.7 About 70% of the popu-
lation uses the public healthcare system, called the Sistema
U´nico de Sau´de (Unified Health System), or SUS, which
provides free medical care to all citizens. According to
DATASUS, the National Database of Healthcare Services,
health care expenditures have increased significantly in
recent years. Between 1995 and 1996 the total cost was
R$ 12 billion (BUS$ 7 billion), while in 2006 it reached
R$ 40 billion (BUS$ 23 billion).8 Despite this growth, the
resources devoted to health care are still insufficient for
the demands of the population, causing serious equity
problems.9 In 2010, only I$ 1.06 million of the I$ 36.7
million spent on healthcare in Brazil, about 3% of the total,
went to mental health care.10
In addition to limited financial resources, there are still
few treatment guidelines for mood disorders that take the
specificities of the Brazilian public health care system
into account.11 Due to insufficient financial resources, the
Brazilian government developed a family health care stra-
tegy for primary health care units that provides greater cove-
rage for mental health care, reaching 95% of Brazilian
municipalities and more than 50% of the population.12
The strategy includes a basic list of free medications that
can be prescribed to patients.
A high prevalence of mental disorders has been obser-
ved among patients at Brazilian primary health care cli-
nics, with around 52% presenting symptoms suggestive
of a mental disorder and 25% presenting symptoms sug-
gestive of depression, although the recognition of mood
disorders is still precarious.12 According to Castelo et al.,
7.6% of patients seeking primary healthcare at clinics in a
large Brazilian city screened positively for BD, although
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only 3.6% were actually diagnosed the disorder.13 There
are few guidelines for primary health care practitioners
regarding mental health, and no data are available to eval-
uate the impact of interventions.14
In order to systematically study the effectiveness of
treatment choices for patients with mood disorders in the
Brazilian public health system, the authors developed phar-
macological treatment algorithms for unipolar depressive
episodes, bipolar depressive episodes, and mixed epi-
sodes based on the list of drugs provided by SUS (Figure 1).
The aim of this study was to verify the effectiveness of these
three algorithms for treating mood disorders in a sample
of patients seeking care in the Brazilian public health care
system.
Methods
A quasi-experimental study design was developed to eval-
uate the effectiveness of treatments for mood disorders in
a public health care context in the city of Porto Alegre, RS,
Figure 1 Treatment algorithms. CZ = carbamazepine; LT = lithium; LSL = lithium serum level; RD = risperidone; VA = valproic
acid.* Response was considered a 50% decrease in Hamilton Rating Scale for Depression baseline scores for major
depressive disorder and bipolar depressive episodes, and a 50% decrease in Hamilton Scale and Young Mania Rating Scale
baseline scores for mixed episode bipolar disorder.
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southern Brazil. Patients with mood disorders were enrol-
led through general practitioner referrals or social media
advertisements. The evaluations were performed between
October 2010 and October 2014 at a public health
outpatient clinic in Porto Alegre (Hospital Psiquia´trico Sa˜o
Pedro). Trained medical students and psychiatry residents
provided clinical care and conducted the evaluations.
Three algorithms were originally developed for treating
mood disorders: one each for unipolar depressive epi-
sodes, bipolar depressive episodes, and mixed episodes.
For unipolar and bipolar depressive episodes, a single-
group, pretest-posttest trial approach was employed.
For mixed bipolar episodes, a multi-arm, randomized,
non-blinded, crossover, pragmatic trial was conducted.
Following simple randomization procedures (i.e., compu-
ter-generated random numbers), mixed bipolar episode
patients were assigned to 1of 3 treatment groups in a 1:1:1
allocation ratio to initially receive lithium, valproic acid or
carbamazepine. The algorithms were developed by a Delphi
panel of experts. The treatment sequence was carried
out according to episode status, as described in Figure 1.
Only medications available in the Brazilian public health-
care system were used: a) sertraline, nortriptyline, and
lithium for unipolar depressive episodes; b) lithium (or
valproic acid when the use of lithium was contraindica-
ted), sertraline, nortriptyline, and risperidone for bipolar
depressive episodes; c) lithium, carbamazepine, valproic
acid, and risperidone for mixed bipolar episodes (Figure 1).
All participants provided written informed consent prior
to participation in this study protocol. The institutional
ethics committee approved all ethical aspects of this
human subject study. The clinical trial registry numbers
are NCT02901249, NCT02870283 and NCT02918097.
Sample
The following eligibility criteria applied to all participants:
a) aged between 18 and 65 years; b) current acute epi-
sode of BD or MDD; c) full capacity to understand and
answer self-applied instruments; d) the presence of symp-
toms in the last 30 days; e) at least 30 days of abstinence
for drug addicts. The exclusion criteria included: a) the
presence of organic brain syndrome (OBS); b) pregnancy
or lactation; c) fulfilling the criteria for psychiatric hospital-
ization.
Procedures and measurements of the study
The study procedures were as follows: 1) sample selec-
tion began by referral from primary municipal health care
clinics; 2) potential participants were given an informative
lecture regarding mood disorders and the parameters of
this study, after which the informed consent forms were
distributed; 3) screening was conducted for BD or MDD
symptoms with the Patient Health Questionnaire (PHQ-9)
for depressive symptoms and the Hypomania Symptom
Checklist Brazilian Version (HCL-32-BV) for manic/hypo-
manic symptoms; 4) diagnostic evaluation was through
a Mini International Neuropsychiatric Interview (MINI) and
a clinical interview for individuals whose screening results
indicated BD or MDD; 5) patients with OBS were excluded
(as recommended by the Mini-Mental State Examination);
6) participants were assigned to a treatment algorithm upon
confirmation of diagnosis; 7) mixed-episode BD participants
were randomized into one of three treatment alternatives in
that algorithm; 8) baseline and demographic assessments
were conducted using standardized semi-structured inter-
views during the first and second visits; 9) in each clinic
visit, the severity of the symptoms were evaluated using
the Clinical Global Impression Scale (CGI), the Hamilton
Rating Scale for Depression (HRSD), and the Young Mania
Rating Scale (YMRS), although individuals diagnosed with
MDD were only evaluated with the CGI and HRSD; 10)
participants were followed-up biweekly and then monthly
after stabilization (the maximum follow-up period was
52 weeks).
The individuals included in the treatment protocols recei-
ved medications that were already available in the public
healthcare system, obtaining them from the hospital’s dis-
pensing pharmacy according to the previously-described
algorithms (Figure 1).
Instruments and measures
Patient Health Questionnaire-9 (PHQ-9)
The PHQ-9 is derived from the Primary Care Evaluation
of Mental Disorders (PRIME-MD) instrument, which was
originally developed to identify five common mental dis-
orders in primary healthcare: depression, anxiety, alcohol
abuse, somatoform disorders, and eating disorders. The
PHQ-9 contains nine self-applied questions and is con-
sidered a relatively quick instrument. It has been validated
for the Brazilian population with adequate sensitivity and
specificity.15
Hypomania Checklist-32 (HCL-32)
The HCL-32, consisting of 32 questions, is a self-admini-
stered instrument that screens for symptoms suggestive
of lifelong hypomania. It is a widely used tool for research
and has demonstrated adequate psychometric character-
istics regarding reliability and validity for the Brazilian
population.16
Mini-Mental State Examination
This instrument is widely used to assess cognitive impair-
ment for clinical and research purposes. The first two
sections explore questions regarding orientation, mem-
ory, and attention. The second section tests the ability to
name objects, follow verbal and written commands, and
copy a polygon. This instrument is easily applied, lasting
5-10 minutes. It has demonstrated reliability, validity, and
acceptance in the clinical field.17
Mini International Neuropsychiatric Interview (MINI) ver-
sion 5.0
This is a short (15-30 minutes) semi-structured diagnostic
instrument that allows diagnoses consistent with the
DSM-IV-TR and ICD-10. It is available in over 30 langua-
ges, including Brazilian Portuguese.18
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Demographic data sheet
The demographic data included age, gender, education
(number of years of schooling), and socioeconomic status.
To determine the latter, the Crite´rio Brasil economic clas-
sification system was used. This system estimates the
purchasing power of urban individuals and families based
on a socioeconomic survey. It characterizes the physical
characteristics of each respondent’s dwelling, the demo-
graphics of all residents, the various household goods pos-
sessed, the public services available (e.g., sewer, water,
power etc.), and household income according to a points
system that determines the economic class.19
Hamilton Rating Scale for Depression (HRSD)
This scale was developed to evaluate and quantify depres-
sion in patients with mood disorders. Its validity and reli-
ability are well established, being of worldwide use. Its
abbreviated version, which was used in this study, consists
of 17 items. The cutoff points are: 7-17 for mild depression,
18-24 for moderate depression, and 25 or more for severe
depression.20
Young Mania Rating Scale (YMRS)
This is the most widely used assessment tool for manic
symptoms. The scale consists of 11 items and is based on
a patient’s subjective report of his or her clinical condition
over the past 48 hours. Additional information is obtained
from clinical observations made during the course of the
interview. Each item is related to a severity score. Four
items are graded 0-8 (irritability, speed/amount of speech,
thought contents, and aggressive and disruptive behavior),
while the remaining seven items are graded 0-4 (eleva-
ted mood, increased activity and energy, sexual interest,
sleep, language-thought disorder, appearance, and insight).
Although baseline scores can vary, it is assumed that a
YMRS score of 12 indicates mania. Clinical trials generally
require YMRS X 20 for inclusion.21
Outcomes
The main outcomes were response to treatment and remis-
sion of symptoms. Treatment response for each diagnostic
protocol was measured in aggregate steps; individual steps
were not assessed. Response to treatment was defined
as a 50% reduction of baseline HRSD results for MDD
and BD depressive episodes, and 50% reductions in both
scales (HRSD and YMRS) for mixed episode BD. Remis-
sion was considered as obtaining three consecutive
asymptomatic scores on the HRSD scale (o 7 points) for
MDD and BD depressive episodes, and on both scales
(HRSDo 7 points and YMRSo 6 points) for mixed bipolar
episodes. Participants who remained asymptomatic for
6-8 months were considered to be in remission, in agree-
ment with the DSM-IV-TR criteria for partial and complete
remission.22
The sample size was calculated to detect a response
to pharmacological intervention with a confidence level of
95% and a statistical power of 90%. Power calculations
revealed that a minimum sample size of 39 patients was
needed in each drug treatment group (total 117 patients).
For mixed bipolar episodes, the expected response rates
were 50% in the lithium group, 50% in the valproic acid
group, and 20% in carbamazepine group. For bipolar
depression treatment, a minimum sample of 93 patients
was calculated to provide an expected response rate of
B30-40%. For unipolar depression treatment, a minimum
sample of 81 patients was calculated to provide an expec-
ted response rate of 70%. These expected response
rates were based on major clinical trials and diagnostic
guidelines. An alpha level of .05 determined significance
in all statistical analyses, which were performed in SPSS
version 19 for Windows. The chi-square test was used to
evaluate categorical variables. Continuous variables were
analyzed using Student’s t-test or ANOVA. Kaplan-Meier
time-event curves were used to analyze response to
treatment and remission of symptoms. The response main-
tenance and remission results were obtained through
intent-to-treat analysis, using a marginal approach for
handling missing data through generalized estimating
equations. The HRSD and YMRS ratings over time were
weighted by the inverse of the estimated probability of
being observed. Changes in scores were compared to
baseline.
Results
The sample consisted of 259 subjects, the majority of
whom were female. The average age was B40 and the
average schooling was nine years. The most common
marital status was cohabitation and the most prevalent
socioeconomic category was class C (lower middle). The
diagnostic prevalences were n=68 (26%) for major depres-
sion, n=78 (30%) for bipolar depression, and n=113 (44%)
for mixed episode BD.
Regarding clinical variables, there was a delay of approx-
imately six years between the onset of symptoms and the
first treatment. After bipolar symptoms had been identified,
there was an additionalB6-year delay until mood stabilizers
were used. Although most patients had moderate depres-
sive symptoms according to HRSD scores, at least 46%
had been hospitalized at least once due to mood symptoms.
All subjects were similar in terms of educational level,
occupational status, clinical characteristics and baseline
symptom scores. These characteristics are described in
Table 1.
Regarding the response to treatment over time, there
was a satisfactory response to the protocols used (Figure 2).
By approximately 20-30 weeks, B80% of the mixed epi-
sode BD patients, B83% of bipolar depression patients,
andB85% of the unipolar depression patients had respon-
ded to treatment. The data suggest that patients with mixed
episode BD take longer than those with depression to
respond. It should be noted that the rates for change in
mental state (mood elevation) were around 13% in
subjects with bipolar depression.
With respect to maintaining treatment gains (Figure 3),
the unipolar depression patients remained more stable
and had lower HRSD scores than those with other dis-
orders. Around 71% of the unipolar depression patients
maintained their response over time, which was higher
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than those with mixed episode BD (47%) or bipolar depres-
sion (66%). There was a statistically significant difference
between unipolar and mixed episode BD response main-
tenance (chi-square p o 0.05).
The time-event curves in Figure 4 show the number of
weeks required for the subjects to present a single asymp-
tomatic measurement on the symptom scales. For the
protocols used in this study, this was expected to occur
at around 20 weeks for 60% of the subjects. However,
regarding the remission maintenance curves (Figure 5), it
was evident that subjects who fulfilled the remission criteria
did so at around 10 weeks, remaining stable thereafter. Of
all the participants in the study, 34.5% achieved complete
remission. Of these, 47.1% had MDD, 34.2% had depres-
sive episode BD, and 26.9% had mixed episode BD; the
difference between MDD and mixed episode BD was stati-
stically significant (chi-square p o 0.05).
Discussion
Our findings show that the proposed treatment algorithms
for these three mood disorder subtypes were effective as
a whole, with response rates around 80%. This is the first
study using Brazilian data to evaluate an algorithm for
treating mood disorders with medication available in the
public health care system. Although the effectiveness of
these medications has already been demonstrated in
several studies, it is relevant to search for interventions
that are appropriate for Brazil’s economic and social
conditions.23-26 These data suggest that the public health-
care system still has major difficulties in treating these
disorders properly, which is probably due to problems of
access, equity, and/or identifying such cases. Despite the
Table 1 Clinical and demographic characteristics
Unipolar depression Bipolar depression Mixed episode p-value*
Age 40.4 (11.4) 41.9 (14.7) 41.7 (11.5) 0.736
Education (years) 8.6 (3.5) 9.9 (3.9) 9.4 (3.8) 0.116
Onset of symptoms (age) 25.2 (13.9) 20.5 (8.1) 22.9 (11.1) 0.081
First treatment (age) 32.4 (12.7) 30.4 (10.9) 30.6 (9.6) 0.567
Time between onset of symptoms and first treatment (years),
median (IQR)
4 (0-12) 7 (1-15) 6 (0-14) 0.564
Time between onset of symptoms and first use of mood
stabilizers (years), median (IQR)
- 12 (4-24) 13 (5-23) 0.808
YMRS (baseline) 3.2 (2.7)w 4.0 (3.1)w 10.1 (5.7)= o 0.001y
HRSD (baseline) 20.5 (6.6) 19.1 (5.9) 19.7 (7.2) 0.418
Female, n (%) 53 (77.9) 61 (78.2) 90 (80.4) 0.905
Marital status (with partner), n (%) 45 (67.2) 54 (71.1) 81 (74.3) 0.593
Employment, n (%)
Unemployed 26 (38.8) 17 (22.4) 38 (34.9) 0.279
Employed 19 (28.4) 27 (35.5) 32 (29.4)
Retired/on leave 22 (32.8) 32 (42.1) 39 (35.8)
Socioeconomic status19, n (%)
A and B 20 (29.9) 15 (19.7) 24 (22.0) 0.196
C 43 (64.2) 47 (61.8) 70 (64.2)
D and E 4 (6.0) 14 (18.4) 15 (13.8)
History of psychiatric hospitalization, n (%) 28 (56.0) 28 (60.9) 33 (46.5) 0.282
Family history of psychiatric disorder, n (%) 53 (94.6) 50 (89.3) 83 (95.4) 0.322
Data presented as mean (standard deviation), unless otherwise specified.
HRSD = Hamilton Rating Scale for Depression; IQR = interquartile range; SD = standard deviation; YMRS = Young Mania Rating Scale.
*Quantitative variables with symmetrical distribution are described as mean (standard deviation) and compared with ANOVA, followed by
the Tukey test. Quantitative variables with asymmetric distribution are described by median (IQR) and compared using the Kruskal-Wallis test.
Categorical variables are described by n (%) and compared with the chi-square test.
wNo significant statistical difference between unipolar and bipolar depression YMRS scores.
=Mixed episode YMRS scores were significantly different from unipolar and bipolar depression YMRS scores.
y p o 0.05.
Figure 2 Kaplan-Meier time-event curves (treatment response).
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satisfactory results obtained in this study, it was surprising
to find that after symptom onset, the subjects had taken
an average of six years to begin treatment and an ave-
rage of 12 years to begin taking mood stabilizers.
A recent study of 5,037 adult residents of the city of
Sa˜o Paulo found that the prevalence of mental disorders
in the 12 months prior to the evaluation wasB30%. Mood
disorders were the second most frequent type of disorder,
affecting 11% of the population. We observed higher pre-
valence rates for mood disorders than Andrade et al.27 In
our study, around 44% of subjects had mixed episode BD,
followed by 30% with bipolar depression, and 26% with
major depression. This was probably due to the sample type,
which was derived from a secondary healthcare service
involving psychiatry specialists. The lower percentages of
major depression patients were probably due to the ease
of identification and treatment of these subjects in primary
healthcare clinics, which is in accordance with previous
findings. Castelo et al. observed that doctors more easily
recognized depressive symptoms in patients who tested
positive on a BD screening at a primary healthcare clinic.
Depressive symptoms were observed in 18.1% of the
bipolar patients, while symptoms suggestive of BD were
recognized in only 2 subjects (3.6%).13 It is also surprising
that, in spite of the high prevalence of psychiatric dis-
orders in big cities like Sa˜o Paulo, healthcare resources
are still scarce. According to Andrade et al., only 8.7% of
the Brazilian population has ever received treatment for
psychiatric disorders, and only 5.3% have received treat-
ment from a sector employing mental health experts.27
These data help explain the treatment delay observed in
our study.
Regarding the effectiveness of the algorithms, high
response rates were found for the different subtypes of
mood disorders. However, since the algorithms are sequen-
tial interventions, featuring combinations of more than one
pharmacological option, the response rates are justified for
being as high as 85% for unipolar depressive episodes,
83% for bipolar depressive episodes, and 80% for mixed
episode BD. According to the (UK) National Institute for
Health and Care Excellence, combining different classes
of antidepressants and adjusting doses are effective
strategies in depression treatment, with response rates
to the first antidepressant ranging from 50 to 75%.28,29
A number of medications are used to treat BD30: ample
evidence indicates that lithium is effective in treating
acute manic episodes and for preventing relapses, while
valproate is becoming more commonly prescribed and
also represents an effective treatment.31-33 Studies on car-
bamazepine, however, suggest that it is less effective in
preventing relapse than lithium or valproate.34
The literature on bipolar depressive disorder is still very
controversial.35,36 Some studies do not recommend using
antidepressants, since they do not accelerate recovery
Figure 3 Hamilton Rating Scale for Depression (HRSD) and Young Mania Rating Scale (YMRS) mean scores (follow-up).
Figure 4 Kaplan-Meier time-event curves (first asymptomatic
measure).
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time compared to monotherapy and may increase the risk
of manic symptom onset.26 Several studies have sugges-
ted monotherapy treatment with drugs such as lamo-
trigine and quetiapine as the first choice for treating
bipolar depression.24,37,38 On the other hand, The Inter-
national Society for Bipolar Disorders (ISBD) set up a task
force in 2013 featuring experts on antidepressant use in
BD patients, which found that antidepressants can bring
some benefit to patients who have responded to them
previously during the acute phase of treatment.39,40 For
the purposes of our study, however, given that neither of
these medications are made available by SUS, we star-
ted patients on lithium. If they were unresponsive after
8 weeks, lithium was associated with sertraline and so
forth, as described above. The mood symptom change
rate was around 13% in subjects with bipolar depression.
This finding is similar to those described by the ISBD, in
which changes in mood state due to antidepressant use
ranged from 3.7 to 29%. According to the consensus, the
tri- or tetracyclic classes, as well as the use of venlafaxine,
are most associated with changes in mood state.40
Another important finding was the time necessary to
obtain a therapeutic response. Our findings indicate that
most subjects responded by the 20th weeks of treatment.
Since this was a sample of individuals who had under-
gone previous treatment, the results may be due to their
more chronic profile, in which an association of different
pharmacological strategies was necessary. Subjects with
mixed bipolar episodes took longer than subjects with
major depression to respond to the treatment algorithms.
Most obtained a response within 30 weeks. This could be
because the response to treatment was only considered
valid if there was a 50% reduction in both the HRSD and
YMRS scales. No other study with this criterion could
be found in the literature. Thus, the response may seem
delayed in comparison to studies that assessed only
manic or depressive symptoms.
In addition to the response to therapy, our findings
suggest that obtaining complete remission is an important
outcome for individuals with mood disorders. In our study,
the complete remission rates were not high (47.1% of
MDD, 34.2% of depressive episode BD, and 26.9% of
mixed episode BD, with significant differences between
MDD and mixed episode BD). These data are similar to
those found in the literature.23,24,38 Nonetheless, partici-
pants who achieved complete remission did so in approxi-
mately 10 weeks and were more stable over time than
those whose symptoms did not go into remission.
Our findings should be considered in light of the study
limitations: i) the study design did not provide compar-
isons with a control or placebo group; ii) neither the inter-
ventions nor the outcomes were blinded; iii) the study
protocol was developed so that only the entire algorithm
could be evaluated rather than individual steps; iv) due to
missing cases , there is a level of uncertainty about longi-
tudinal data; v) there were no dose-dependent or side
effect evaluations. Despite these limitations, as a real-life
assessment, many of the challenges found in clinical mental
health practice were present, and the limited therapeutic
choices provided by SUS were addressed. Hence, the
results could contribute to the body of knowledge on public
health and mental disorders, especially regarding mood
disorder treatments for primary care providers.
In conclusion, great strides have recently been made in
understanding mood disorders. Since these disorders
have extremely heterogeneous presentations, identifying
cases and prescribing appropriate treatment can still be
a challenge. Our study showed response rates around
80%, suggesting that treatments can be more effective
if they are coupled with longer follow-up periods. The
Figure 5 Hamilton Rating Scale for Depression (HRSD) and Young Mania Rating Scale (YMRS) mean remission scores
(follow-up).
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remission of symptoms is still the main desired outcome.
In our findings, participants who achieved remission recov-
ered more rapidly and remained more stable over time. In a
country of continental dimensions such as Brazil, in which
at least 11% of the population is affected by mood dis-
orders, the development of guidelines to assist in obtaining
proper treatment for these symptoms should be highly
beneficial and could provide better quality of life for these
people. It is our expectation that the findings of this prag-
matic trial could facilitate the development of future studies
and guidelines, providing useful hypotheses toward the
implementation of mental health policies for SUS users.
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